Antimicrobial use and antimicrobial resistance trends in Canada: 2014.

BACKGROUND: There is a global concern that the emergence of antimicrobial resistance (AMR) threatens our ability to treat infectious diseases. The Canadian Antimicrobial Resistance Surveillance System (CARSS) was created in response to the Government of Canada's commitment to addressing AMR. CARSS integrates information from nine different national surveillance systems for tracking antimicrobial use (AMU) and AMR in both humans and animals to inform AMU/AMR research and policy. OBJECTIVE: To provide highlights of CARSS data on antimicrobial use in humans and animals, AMR trends in human infections in both hospital and community settings and AMR bacteria found in food production animals. METHODS: Information on AMU in animals and humans is purchased and additional information on AMU in animals is collected through the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). AMR data in humans focuses on first priority organisms. Data on priority organisms for hospital-based AMR is collected through Canadian Nosocomial Infection Surveillance Program (CNISP), Canadian Tuberculosis Laboratory Surveillance System (CTBLSS), Canadian Tuberculosis Laboratory Surveillance System (CTBRS), Canadian Tuberculosis Reporting System (CTBRS) and CIPARS. Data on community-based AMR is collected through CTBLSS, CTBRS, CIPARS, the Antimicrobial-resistant Neisseria gonorrhoeae Surveillance System (ARNGSS) and the National Surveillance of Invasive Streptococcal Disease (NSISD). AMR data on animals is collected through CIPARS. RESULTS: In terms of antibiotic usage in 2014, approximately 82% of antimicrobials were directed to food production animals, 18% to humans and less than one percent each to companion animals (e.g., pets) and crops. Over the past five years, 73% of antimicrobials distributed to food production animals belonged to the same classes as those used in human medicine. Antibiotic usage in humans has remained relatively stable. Trends in 2014 for AMR in hospitals include declining rates of hospital-acquired Clostridium difficile to 3.4 cases per 1,000 patient admissions, methicillin-resistant Staphylococcus aureus (MRSA) infections to 2.89 cases per 10,000 patient days and vancomycin-resistant Enterococci (VRE) to 0.45 cases per 10,000 patient days. Resistance to a number of antimicrobials used to treat Streptococcus pneumoniae has decreased since the introduction of pneumococcal vaccine in 2010. In contrast, trends in 2014 for AMR in the community included increasing rates of community-acquired N. gonorrhoeae - 52.4% of isolates were resistant to at least one antibiotic. Trends for carbapenem-resistant Enterobacteriaceae (CRE) were stable at 0.22 cases per 10,000 patient days. Also, between 2004 and 2014, nine percent of tuberculosis (TB) culture positive cases were resistant to at least one first line anti-tuberculosis drug and this has remained relatively stable over that time. Trends in 2014 for AMR in food production animals showed decreasing resistance of Escherichia coli and Salmonella species to third-generation cephalosporins (ceftriaxone) in poultry associated with a decrease in cephalosporin use on chicken farms, but resistance to ciprofloxacin in Campylobacter species in chicken and cattle has been increasing. CONCLUSION: Overall, antibiotic use in humans has not declined despite concerns about overuse. Although resistance rates of C. difficile, VRE, MRSA and AMR S. pneumoniae have been gradually decreasing and drug-resistant tuberculosis and CRE have remained stable, community-associated drug-resistant N. gonorrhoeae has been increasing. Although efforts to decrease antibiotic use in animals have been met with some success, AMR continues to occur in fairly high levels in food production animals.

A summary of the Transfusion Error Surveillance System: 2008 - 2011.

BACKGROUND: Although Canada has one of the safest blood systems in the world, transfusion errors can occur at any time from the moment of collection through to the transfusion of blood and blood products. The Transfusion Error Surveillance System (TESS) was initiated by the Public Health Agency of Canada (the Agency) to monitor transfusion-related errors occurring at any point in the transfusion chain. OBJECTIVE: To offer an analysis of the TESS data reported from 2008 to 2011. METHODS: Between 2008 and 2011, 12 to 15 hospitals from four provinces participated in the TESS. Reports on all transfusion-related errors were sent electronically on a quarterly basis to the Agency where they were consolidated, cleaned, validated and analyzed. Different types of transfusion errors were categorized by time of discovery (pre- or post-transfusion) and their potential impact on the patient's health. The occurrence rates of different types of errors were calculated using corresponding denominator data. Results were grouped by the transfusion capacity of reporting hospitals. RESULTS: Between 2008 and 2011, a total of 34,088 transfusion-related errors were reported. Of these, 33,622 (98.6%) were detected prior to transfusion. The most commonly reported were errors related to the collection (40.1%) and handling (10.4%) of blood samples. Of the remaining 466 (1.4%) that were detected after transfusion, 66 were of high potential severity and 16 of them resulted in adverse reactions in recipients. Inappropriate / incorrect / no product order accounted for over 56% (n=9) of these errors and the most common adverse reaction was transfusion-associated circulatory overload which occurred in eight (50%) of the patients that developed adverse reactions. CONCLUSION: The TESS data from 2008 to 2011 demonstrates that blood transfusions are both safe and efficient in Canadian hospitals participating in the surveillance and also highlights the most common and most harmful errors that may be targeted for corrective actions.

A summary of the Transfusion Transmitted Injuries Surveillance System: 2006 - 2012.

BACKGROUND: The Transfusion Transmitted Injuries Surveillance System (TTISS) is a pan-Canadian surveillance system established by the Public Health Agency of Canada (the Agency) in partnership with the provinces and territories to capture non-nominal data on adverse transfusion reactions in Canadian hospitals providing transfusion services with the overarching goal of improving patient safety. OBJECTIVE: To summarize transfusion-related adverse reactions reported to the TTISS between 2006 and 2012. METHODS: Hospitals from 10 provinces and two territories participated in the TTISS by collecting and submitting data on all transfusion-related reactions or injuries to the provincial / territorial blood coordinating offices. This data was sent to the Agency where it was consolidated, cleaned, validated and analyzed by type of reactions or outcome. Corresponding rates were also calculated using the total number of units of blood components transfused as a denominator. RESULTS: From 2006 to 2012, a total of 3,957 adverse reactions were reported to the TTISS, excluding minor allergic reactions. Of these, 2,920 (73.8%) were related to transfusion of blood components and 1,036 (26.2%) were from the transfusion of blood products. Among reactions related to the transfusion of blood components, the most common were: transfusion-associated circulatory overload (n = 1,242, 42.5%), severe allergic / anaphylactic / anaphylactoid reactions (n=411; 14.1%) and hypotensive reactions (n=298; 10.2%). Among those related to transfusion of blood products, close to one-half were intravenous immunoglobulin (IVIG) headache (n=295; 28.5%) or delayed hemolytic reaction (n=175; 16.9%). Death definitely attributable to transfusion was extremely rare: only one case diagnosed with transfusion-related acute lung injury was identified between 2006 and 2012. CONCLUSION: The majority of reactions attributable to transfusion resulted in minor or no sequelae. Strengthening the TTISS will improve the monitoring of adverse transfusion reactions which is one of the key components of an overall patient safety strategy. Current initiatives to improve data quality include the development of transfusion-associated circulatory overload / transfusion-related acute lung injury recognition algorithm and the collection of appropriate denominators for the calculation of the rates of adverse reactions from the transfusion of blood products.

Developing a cells, tissue and organ surveillance system.

BACKGROUND: An increasing number of cell, tissue and organ transplant procedures take place each year in Canada, including procedures in clinics, physician and dental offices. The Public Health Agency of Canada (the Agency) is leading the development of a Cell, Tissue and Organ Surveillance System (CTOSS). OBJECTIVE: To create timely, useful and relevant national-level transplantation adverse event data by supporting the development and / or enhancement of provincial and territorial data collection systems. METHODS: Minimum data elements and definitions were established for tissues based on definitions established in the European Union and the United States. Data collection on adverse events related to human allograft tissue transplants began in April 2011 at pilot sites in Alberta, Ontario, Quebec, New Brunswick and Nova Scotia. RESULTS: By December 2013, eight tissue transplantation adverse events were reported. Seven involved corneal tissue and one involved cardiovascular tissue. CONCLUSION: A fully developed CTOSS could increase Canadian capacity to improve patient safety. Data collection and analysis could increase the potential for a better understanding of transplantation adverse events, subsequently inform the development of strategies for overall prevention and reduce the severity of such events. The next steps in developing CTOSS will be to establish data elements and definitions for the cell and organ transplant components of the system and increase the number of pilot sites.

Clinical and laboratory practices in investigation of suspected transfusion-transmitted bacterial infection: a survey of Canadian hospitals.

Transfusion of a bacterially contaminated blood product can have serious consequences. We undertook an electronic survey of representative Canadian hospitals to determine current clinical and laboratory practices for investigating such reactions, prior to the development of national guidelines. There was considerable variability in symptoms and signs that would trigger investigation of possible contamination. The most frequent laboratory investigations performed were aerobic blood cultures of recipients and the residual component. If there is no residual product in the component bag, 36% of respondents would use a segment to perform testing. Guidelines could be helpful in improving and standardizing these practices.

Cross sensitivity of skin rashes with antiepileptic drugs.

BACKGROUND: Skin rashes are a well known complication of antiepileptic drug (AED) treatment. It has also been recognized that some patients will develop rashes from multiple AEDs (cross sensitivity). There are very few studies that have attempted to determine the frequency of cross sensitivity among AEDs. METHODS: Charts of all patients attending an epilepsy outpatient clinic were reviewed to determine AED exposure and the occurrence of a rash from AEDs. RESULTS: 633 patients had 1,875 exposures to 14 AEDs. Rashes occurred from carbamazepine (N = 27), phenytoin (N = 21), phenobarbital (N = 5) and lamotrigine (N = 1). A rash from 2 or more AEDs occurred in 14 patients and involved predominantly carbamazepine and phenytoin. Among the patients exposed to both phenytoin and carbamazepine 10/17 (58%) of patients with a rash from phenytoin also had a rash from carbamazepine; conversely 10/25 (40%) patients with a carbamazepine rash also had a rash from phenytoin. 4/5 patients with a phenobarbital rash were sensitive to carbamazepine and/or phenytoin. Amongst the other most commonly used AEDs no rashes occurred from valproic acid or clobazam. CONCLUSIONS: The cross sensitivity rate for rashes involving carbamazepine and phenytoin is 40-58%. If a rash develops from either of these AEDs, valproate or clobazam are safe alternatives.

A severe multisystem reaction to sulindac.

We present a case of a severe reaction to sulindac. A 30-year-old woman with quiescent systemic lupus erythematosus received sulindac for nonspecific migrating chest pain. An initial course of therapy produced an unrecognized sensitization to the drug with a febrile illness and rash. Readministration of the drug caused an anaphylactoid reaction as well as evidence of cardiovascular, hepatic, pulmonary, and hematologic dysfunction. The patient's illness had evidence of types I, II, and III hypersensitivity reactions.